Published in Cancer Res on October 01, 2002
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 2.61
Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev (2004) 2.16
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther (2011) 1.76
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol (2009) 1.42
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci (2008) 1.36
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A (2013) 1.32
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A (2009) 1.17
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest (2011) 1.16
Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. Cancer Res (2012) 1.15
Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res (2010) 1.15
Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia (2011) 1.14
STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med (2009) 1.13
The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia (2005) 1.12
Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin. Cancer Res (2011) 1.09
GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Mol Cancer Res (2009) 1.09
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets (2010) 1.07
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene (2010) 1.07
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget (2013) 1.05
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A (2009) 1.05
Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia (2008) 1.03
Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. Cancers (Basel) (2013) 1.01
Common astrocytic programs during brain development, injury and cancer. Trends Neurosci (2009) 1.01
Neuronal stem cells in the central nervous system and in human diseases. Protein Cell (2012) 0.97
Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience (2010) 0.96
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther (2010) 0.95
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci (2016) 0.95
Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist (2012) 0.95
Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer (2008) 0.94
Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochim Biophys Acta (2013) 0.93
Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med (2009) 0.93
Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys J (2011) 0.93
Molecular biology of gliomas: present and future challenges. Transl Med UniSa (2014) 0.92
A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene (2010) 0.92
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro. Neuro Oncol (2013) 0.91
Brain cancer stem cells: current status on glioblastoma multiforme. Cancers (Basel) (2011) 0.90
Gliotypic neural stem cells transiently adopt tumorigenic properties during normal differentiation. Stem Cells (2009) 0.90
iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med (2013) 0.89
Brain stem cells as the cell of origin in glioma. World J Stem Cells (2014) 0.88
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
Contribution of tumor heterogeneity in a new animal model of CNS tumors. Mol Cancer Res (2014) 0.88
Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol (2007) 0.88
Retinoblastoma loss modulates DNA damage response favoring tumor progression. PLoS One (2008) 0.88
STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation. J Neurosci (2012) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS One (2011) 0.86
Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World J Stem Cells (2014) 0.86
Differential transformation capacity of neuro-glial progenitors during development. Proc Natl Acad Sci U S A (2013) 0.85
Ink4a/Arf loss promotes tumor recurrence following Ras inhibition. Neuro Oncol (2011) 0.83
Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma. J Neuropathol Exp Neurol (2012) 0.82
Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes Cancer (2013) 0.82
PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. BMC Cancer (2010) 0.81
What underlies the diversity of brain tumors? Cancer Metastasis Rev (2013) 0.81
Maintenance of critical properties of brain tumor stem-like cells after cryopreservation. Cell Mol Neurobiol (2010) 0.81
NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis (2010) 0.81
Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy (2016) 0.80
Oncogenic KRAS promotes malignant brain tumors in zebrafish. Mol Cancer (2015) 0.80
Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics (2014) 0.80
Drosophila melanogaster as a model system for human brain cancers. Glia (2011) 0.80
Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells Int (2016) 0.80
Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol (2012) 0.80
Some speculation on the origin of glioblastoma. Neurosurg Rev (2006) 0.80
The taxonomy of brain cancer stem cells: what's in a name? Oncoscience (2014) 0.79
The potential of the brain: plasticity implications for de-differentiation of mature astrocytes. Cell Mol Neurobiol (2009) 0.79
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53. Am J Cancer Res (2015) 0.78
Induction of histiocytic sarcoma in mouse skeletal muscle. PLoS One (2012) 0.78
Oligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes. J Neurosci (2013) 0.78
Pediatric gliomas as neurodevelopmental disorders. Glia (2015) 0.77
Exploiting metabolic differences in glioma therapy. Curr Drug Discov Technol (2012) 0.77
Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev (2017) 0.77
Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathol (2016) 0.76
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp (2015) 0.76
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. Curr Protoc Pharmacol (2016) 0.75
Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements. Stem Cells Cloning (2009) 0.75
Pleiotrophin enhances PDGFB-induced gliomagenesis through increased proliferation of neural progenitor cells. Oncotarget (2016) 0.75
Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma. Cell Cycle (2017) 0.75
The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy. Cytotechnology (2003) 0.75
Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future. Oncotarget (2016) 0.75
The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology. Future Neurol (2008) 0.75
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol (2005) 2.58
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell (2012) 2.50
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 2.39
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
The brain tumor microenvironment. Glia (2011) 2.13
Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem (2004) 2.07
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest (2004) 2.02
Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97
Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 1.96
Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res (2003) 1.96
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med (2004) 1.76
Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics (2002) 1.75
Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 1.73
Radiation resistance and stem-like cells in brain tumors. Cancer Cell (2006) 1.70
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
Cancer stem cells and survival pathways. Cell Cycle (2008) 1.66
The brain tumor microenvironment. Glia (2012) 1.66
Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol (2007) 1.66
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res (2005) 1.65
The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res (2008) 1.62
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 1.60
p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo. Cell Cycle (2010) 1.59
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol (2009) 1.59
Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene (2004) 1.58
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett (2005) 1.53
Textiloma (gossypiboma) mimicking recurrent intracranial tumor. Arch Pathol Lab Med (2004) 1.51
Origin of chordoid glioma of the third ventricle. Arch Pathol Lab Med (2006) 1.51
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol (2007) 1.47
Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res (2005) 1.47
Nemaline myopathy: a possible late complication of Hodgkin's disease therapy. Hum Pathol (2003) 1.47
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res (2013) 1.46
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One (2012) 1.44
c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia (2003) 1.40
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst (2010) 1.39
Epithelioid pituicytoma. World Neurosurg (2011) 1.39
Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene (2002) 1.39
Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci (2009) 1.38
Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci U S A (2012) 1.37
Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS One (2011) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol (2012) 1.36
Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol (2002) 1.35
Identification of combination gene sets for glioma classification. Mol Cancer Ther (2002) 1.35
Intermittent lumbar puncture in rats: a novel method for the experimental study of opioid tolerance. Anesth Analg (2006) 1.33
DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res (2011) 1.33
The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol (2004) 1.33
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem (2006) 1.32
Herpes simplex encephalitis in patients with cancer. J Neurooncol (2011) 1.32
Pulmonary artery sarcoma: a clinicopathologic and immunohistochemical study of 12 cases. Am J Clin Pathol (2006) 1.32
Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus (2002) 1.31
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology (2008) 1.30
Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev (2008) 1.30